- Home
- EVMN vs CBLL Comparison
EVMN vs CBLL Comparison
Compare EVMN & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVMN | CBLL |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | 48 | 280 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 869.1M | 750.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EVMN | CBLL |
|---|---|---|
| Price | $13.32 | $19.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $43.88 | $23.20 |
| AVG Volume (30 Days) | ★ 1.0M | 345.1K |
| Earning Date | 06-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.57 |
| Revenue Next Year | N/A | $28.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.89 | $10.85 |
| 52 Week High | $33.20 | $24.33 |
Technical Indicators
Market Signals| Indicator | EVMN | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 57.57 |
| Support Level | N/A | $18.91 |
| Resistance Level | $20.37 | $19.56 |
| Average True Range (ATR) | 1.74 | 0.82 |
| MACD | -0.52 | 0.23 |
| Stochastic Oscillator | 0.59 | 66.67 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About CBLL CeriBell Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.